Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials
Event:
ESC Congress 2023
Topic:
Lipid-Lowering Agents
Session:
PCSK9 inhibitors and inclisiran
